Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy

Lucia Scarabel, Marica Garziera, Sara Fortuna, Fioretta Asaro, Giuseppe Toffoli & Silvano Geremia

We here explore the soluble Human Leukocyte Antigen-G (sHLA-G) expression level as clinical biomarker in metastatic colorectal cancer (mCRC). To this aim the sHLA-G protein was measured in plasma samples of 40 patients with mCRC treated with the FOLFIRI (irinotecan (CPT-11) plus 5-fluorouracil (5-FU) and leucovorin (LV)) regimen. The results suggest a link between HLA-G levels and irinotecan (CPT-11) pharmacokinetic, leading to hypothesize a molecular interaction between sHLA-G and CPT-11. This interaction was confirmed experimentally by fluorescence spectroscopy. HLA-G is known to exist in a number of polymorphs that affect both the protein expression levels and its peptide-binding cleft. The interaction between HLA-G polymorphs and CPT-11 was explored by means of computational modelling, confirming the hypothesis that CPT-11 could actually target the peptide binding cleft of the most common HLA-G polymorphs.

The possibility to measure and monitor the level of soluble Human Leukocyte Antigen-G (sHLA-G) in body fluids such as plasma, serum, ascites, cerebrospinal fluids exudates, and the identification of early variations in HLA-G levels is emerging as a precious tool for the early diagnosis of cancer diseases and to monitor the appearance of recurrences. Although tissue and/or soluble HLA-G were already observed upregulated in patients with several cancers compared to healthy donors, further investigation about its therapeutic role is still needed.

HLA-G exerts immunoinhibitory activities mainly through a direct interaction with ILT receptors on effector cells and an indirect mechanism through regulatory cells. A specific inhibitory interaction of HLA-G expressed by target cells against TILs, in particular CD8+ ILT2+ T cell cytotoxicity, was reported as a mechanism of tumor escape from immunosurveillance. Recently, Pagès and colleagues showed the relevance of a new method called Immunoscore to stratify patients evaluating the presence of CD3+ and CD8+ T-cell effectors (TILs) and ensuring a more precise treatment with a better prognostic value in colon cancer. However, not all the independent evaluators are concordant for the TIL evaluation on hematoxylin and eosin stained and the concordant analysis was performed only on 10% of whole cohort (n = 268 cases).

The clinical relevance of sHLA-G expression has recently suggested that a stratification based on sHLA-G levels could also be an independent predictive and prognostic factor for patients with colorectal cancer (CRC) because its presence could alter the TILs interaction and then the immune system response. Moreover, these patients are often administered with irinotecan (CPT-11) as part of their therapy. CPT-11 is an antineoplastic drug present in several regimens used in combination with other chemotherapeutics to treat metastatic CRC (mCRC). It is also investigated for clinical applications in gastric, lung, pancreas, cervix, and ovarian cancers. CPT-11 acts as antineoplastic enzyme inhibitor of the DNA topoisomerase I, interfering with the replication of the DNA and inducing double-breaks in the strand, causing cell death. Its therapeutic efficacy is partially reduced by the occurrence of severe toxicities, such as diarrhea and neutropenia, that limits the irinotecan...
A recent study evaluated the association between sHLA-G levels in plasma samples and clinical characteristics of patients with CRC, suggesting that sHLA-G could be a promising biomarker for predicting treatment efficacy and toxicity profile. The association between sHLA-G levels and specific polymorphisms in coding and non-coding regions of the HLA-G gene was also investigated. The study found that certain polymorphisms are associated with higher levels of sHLA-G, which could potentially be used as a biomarker for identifying patients who may benefit from lower doses of irinotecan.

The HLA-G gene encodes a non-classical major histocompatibility complex (MHC) class I molecule. It has a highly complex metabolism with multiple isoforms, including soluble and membrane-bound forms. The soluble forms are shed through proteolytic cleavage from the cell surface, while the membrane-bound forms are expressed on the cell surface.

The HLA-G gene is characterized by a limited allelic variation, with only 69 alleles identified to date. The most prevalent allele is HLA-G*01:01, followed by HLA-G*01:04, HLA-G*01:22, and HLA-G*01:14. These alleles have been associated with high and low sHLA-G levels, respectively.

In vitro studies have shown that the HLA-G molecule can interact with various immune cells, including dendritic cells (DCs) and T cells. This interaction is thought to play a role in the immune response and the development of immune tolerance.

The HLA-G molecule is also involved in the detoxification of chemotherapeutic drugs, such as irinotecan. Irinotecan is a topoisomerase I inhibitor that is widely used in the treatment of CRC. However, it has a highly complex metabolism and can be converted into toxic metabolites, leading to severe toxicity and treatment failure.

Research has shown that the expression of sHLA-G is correlated with the activity of metabolic enzymes, such as UGT1A1. The UGT1A1 polymorphism is associated with decreased detoxification of irinotecan, leading to increased toxicity and treatment failure.

In conclusion, the association between sHLA-G levels and clinical characteristics of patients with CRC and irinotecan suggests that sHLA-G could be a promising biomarker for predicting treatment efficacy and toxicity. Further studies are needed to validate these findings and to explore the potential clinical utility of sHLA-G as a biomarker for individualizing chemotherapy treatment.
and the interaction between HLA-G polymorphs (or mutants) and CPT-11 was explored in silico by means of docking and molecular dynamics simulations.

**Results**

**Clinical parameters and soluble HLA-G plasmatic levels.** Untreated plasma and blood samples collected from 40 patients with mCRC prior to administration of FOLFIRI (irinotecan (CPT-11) plus 5-fluorouracil (5-FU) and leucovorin (LV)) regimen, were considered for this analysis. In this group (Table 1), with predominance of women (n=25, 62.5%) and of rectum and right colon as primary tumor site (n=18, 45.0% and n=14, 35.0%, respectively), the median age was 57.9 years (range 26.5–75.5) and median follow-up was 15.42 months (range: 1.15–31.48 months). Most of the patients with mCRC were staged III-IV at the time of diagnosis (n=35, 87.5%), received radical surgery (n=26, 65.0%), and 8 out of 40 (20.0%) patients had more than 2 metastatic sites at the time of enrolment in the study.

To measure the sHLA-G a commercially available ELISA kit was used. The median sHLA-G was 116.4 U/ml (range: 12.8–1552.7). The clinicopathological parameters of the patients with mCRC were stratified according to the sHLA-G plasma levels measured (Table 1). No significant associations were observed except for the number of metastatic sites. Significantly lower sHLA-G levels (p=0.0214, Fig. 2a) were observed in patients with 1 metastatic site (median 84.1 U/ml) compared with patients with more than 1 metastatic site that were associated with a higher sHLA-G concentration (median 150.1 U/ml). This result was also confirmed (p=0.0486) when patients were stratified according to 1 metastatic site, 2 metastatic sites and more than 2 (>2) extra-regional lesions (Fig. 2b).

**Correlation between sHLA-G levels and pharmacokinetic parameters.** Based on the possible role of the sHLA-G plasmatic level in patients with mCRC treated with first-line FOLFIRI regimen, we further investigated the possible correlation between sHLA-G levels and pharmacokinetic parameters (PK) previously reported by our group ($^{43}$CPT-11 AUC, $^{38}$SN38 AUC (the CPT-11 active form), $^{38}$SN38G (inactive glucuronidation form of irinotecan), GR (glucuronidation ratio) and BI (biliary index). The BI was defined as the product of the CPT-11

| Characteristic               | n  | (%)  | sHLA-G median (range, U/ml) | p*   |
|-----------------------------|----|------|----------------------------|------|
| mCRC                        |    |      | 116.4 (12.8–1552.7)         |      |
| Age, yrs                    |    |      |                            |      |
| ≤61.6                       | 20 | 50.0 | 117.9 (43.1–1552.7)         | 0.8604|
| >61.6                       | 20 | 50.0 | 116.4 (12.8–806.0)          |      |
| Gender                      |    |      |                            |      |
| Woman                       | 25 | 62.5 | 121.4 (43.1–1552.7)         | 0.1464|
| Man                         | 15 | 37.5 | 91.5 (12.8–254.5)           |      |
| Primary tumor site           |    |      |                            |      |
| Colon                       | 22 | 55.0 | 110.0 (12.8–199.7)          | 0.5054a|
| Rectum                      | 18 | 45.0 | 123.6 (43.1–1552.7)         | 0.8112|
| Left colon                  | 8  | 20.0 | 113.8 (12.8–199.7)          |      |
| Right colon                 | 14 | 35.0 | 94.2 (44.4–806.0)           |      |
| Radical surgery             |    |      |                            |      |
| Yes                         | 26 | 65.0 | 125.8 (48.4–806.0)          | 0.1605|
| No                          | 14 | 35.0 | 89.3 (12.8–806.0)           |      |
| Stage at diagnosis          |    |      |                            |      |
| I–II                        | 5  | 12.5 |                            |      |
| III–IV                      | 35 | 87.5 |                            |      |
| Adjuvant (radiotherapy or chemotherapy) | | | | |
| No                          | 26 | 65.0 | 102.0 (12.8–1552.7)         | 0.6000|
| Yes                         | 14 | 35.0 | 123.6 (61.8–366.5)          |      |
| Number of metastatic sites  |    |      |                            |      |
| 1                           | 17 | 45.9 | 84.1 (43.1–711.4)           | 0.0214|
| >1                          | 20 | 54.1 | 150.1 (12.8–1552.7)         |      |
| 2                           | 12 | 32.4 |                            |      |
| 3                           | 2  | 5.4  |                            |      |
| 4                           | 5  | 13.5 |                            |      |
| 5                           | 1  | 2.7  |                            |      |
| >2                          | 8  | 21.6 |                            | 0.0486|

Table 1. Demographic and clinical characteristics of 40 eligible patients with mCRC and association of sHLA-G plasma expression with their clinicopathological parameters. *Mann-Whitney-test; $^{a}$p = 0.759 with Kruskal-Wallis test comparing rectum, left colon and right colon.
AUC and the ratio of the SN38 AUC over the SN38G AUC: $\text{BI} = \frac{[\text{AUC(CPT11)}]}{[\text{AUC(SN38)}]} / \frac{[\text{AUC(SN38G)}]}{[\text{AUC(SN38G)}]}$. For this analysis, PK values were available for 22 patients that were stratified into two subgroups according to the sHLA-G median value (86.4 U/ml) measured: above (sHLA-G High) and equal or below (sHLA-G Low) the median sHLA-G value. Patients with sHLA-G High were associated with lower levels of plasmatic CPT-11 (median 16.3 $\mu$mol*h, range: 10.7–29.9) and patients with sHLA-G Low with higher levels of CPT-11 (median 25.5 $\mu$mol*h, range: 13–40.8) ($p = 0.0216$, Fig. 3a). Similarly, a significant inverse correlation was found between sHLA-G and BI ($p = 0.0181$, Fig. 3b): patients with sHLA-G High were associated with lower levels of BI (median 3.6 $\mu$mol*h, range: 1.4–7.7) and patients with sHLA-G Low with increased levels of BI (median 7.6 $\mu$mol*h, range: 3.2–12.1). No correlation was found with SN38 AUC, SN38G, or GR (Fig. 3c–e).

**HLA-G/irinotecan interaction.** The inverse relation observed between sHLA-G and CPT-11 AUC levels suggested an irinotecan-based effect on sHLA-G. We thus explored the possible molecular interactions between HLA-G and irinotecan in vitro and in silico.

The interaction between HLA-G*01:01 and CPT-11 was experimentally investigated by spectrophotometric analysis. The emission spectra of the HLA-G overlaps considerably with the absorption spectra of CPT-11 (Fig. 4a) suggesting the possibility to use the fluorescence resonance energy transfer (FRET) between HLA-G and CPT-11. The measurements were performed in water solutions because no appreciable variation in the shape and intensity of CPT-11 emission spectra was observed in PBS (Fig. 4b). A huge variation of the fluorescence intensity, compared to the signals produced by the HLA-G and CPT-11 alone, was observed when the HLA-G and CPT-11 solutions were mixed in a 1:1 ratio (Fig. 4b). The large increase of the fluorescence signal attributable to the FRET confirmed the interaction between the HLA-G and CPT-11. A titration assay further confirmed the dose response signal with a significant increase of the CPT-11 fluorescence (Fig. 4c). The fit of the datapoints collected at 430 nm

![Figure 2](https://example.com/figure2.png)

**Figure 2.** Statistical comparison (a) between 1 metastatic site and >1 metastatic site based on Mann-Whitney test, and (b) between 1, 2 and >2 metastatic site based on Krustal Wallis test.

![Figure 3](https://example.com/figure3.png)

**Figure 3.** Distribution of pharmacokinetic parameters according to plasma sHLA-G High or Low group: (a) CPT-11 AUC, (b) biliary index, (c) SN38 AUC, (d) SN38G AUC, (e) glucuronidation ratio.
The interaction between HLA-G and CPT-11 was then investigated by computational modelling. For the modelling we considered the α1 and α2 domains of four HLA-G polymorphs: the most common protein HLA-G*01:01 (Fig. 5a), the p.Thr31Ser polymorph HLA-G*01:03 (Fig. 5b), the p.Leu110Ile polymorph HLA-G*01:04 (Fig. 5c), and the mutant HLA-G*01:05 N (Fig. 5d). This latter truncated protein, as a consequence of the changes in the reading frame due to the deletion in codon 130 and the creation of a premature stop codon after 60 residues, does not possess the S-S bridge between Cys77 and Cys140, and the Cys179-Cys235 bridge. The polymorphism in codon 258 p.Thr258Met (defining the HLA-G*01:06) is localized in the α3 domain and was not investigated. The selected polymorphs were modelled by homology modelling.

The irinotecan size and shape are comparable to that of the small peptides presented on the peptide-binding cleft defined by the α1 and α2 domains of MHC class I. Then, the peptide-binding cleft was chosen as putative binding site for the CPT-11. One drug molecule was docked to the cleft of each HLA-G polymorph. The conformation with the lowest score found for CPT-11 in HLA-G*01:01 appears elongated into the pocket (Fig. 5a) similarly to that found for the binding peptides. The molecule is bent towards the α2 domain. The same pose was found in the docking results for polymorphs HLA-G*01:03 (Fig. 5b), and HLA-G*01:04 (Fig. 5c). The glucuronidation seemed to destabilise SN38G position in the cleft leading to several competing poses: two are the recurring poses one of which with the same conformation and position as that observed for CPT-11 in all polymorphs (Supplementary Fig. 1). The glucuronidation created a larger number of competing poses, SN38 does not adopt the same conformation as CPT-11, and it was not found to assume the same pose in G*01:01. In agreement with its reduced size not filling the available cleft space, the shorter SN38 appears most often translated in the cleft with respect to CPT-11 in all polymorphs (Supplementary Fig. 1). The interaction between the free irinotecan (gray line) and the fit (blue curve) to the experimental fluorescence data (red points) at 430 nm of panel c. The adjusted coefficient of determination ($R^2$) relative to the fitted curve is also indicated. Errorbars are smaller than datapoints. All the emission spectra were recorded with an excitation wavelength of 280 nm.

Figure 4. (a) Overlap (shaded area) between absorbance spectrum of CPT-11 50μM (green) and emission spectrum of HLA-G 1μM (red) suggesting FRET. (b) Emission spectra of CPT-11 in water (green), CPT-11 in 1μM PBS (yellow), 0.1μM HLA-G (red), and HLA-G 1μM with CPT-11 1μM (ratio 1:1) in water (blue). (c) Fluorescence emission spectra (mean of 4 scans) of HLA-G 1μM with the addition of CPT-11 at 0.1, 0.2, 0.4, 0.8, 1, 2, 4, 8μM. (d) Comparison between the free irinotecan (gray line) and the fit (blue curve) to the experimental fluorescence data (red points) at 430 nm of panel c. The adjusted coefficient of determination ($R^2$)
Figure 5. Representative conformation of each HLA-G polymorph and the docked CPT-11 for (a) HLA-G*01:01, (b) HLA-G*01:03, (c) HLA-G*01:04, (d) HLA-G*01:05 N. In all cases the S-S bridge forming Cys77 and Cys140 are highlighted. In (a–c) the mutated amino acids with respect to HLA-G*01:01 (at positions 31 and 110) are represented with their van der Waals spheres, and in (d) the substituted 60 aa peptide after Asp 129 is highlighted in a darker colour.

Figure 6. Comparison between representative conformations of CPT-11/HLA-G*01*01 (top panels) and CPT-11/HLA-G*01*5 N (bottom panels): (a) schematic diagram of the interaction between CPT-11 and HLA-G*01:01 and surface electrostatic (Coulomb) potential of (b) CPT-11, (c) HLA-G*01:01, and (d) their complementarity; (e) schematic diagram of the interaction between CPT-11 and HLA-G*01:05 N and surface electrostatic (Coulomb) potential (kcal·mol⁻¹·e⁻¹) of (f) CPT-11, (g) HLA-G*01:05 N, and (h) their complementarity. In (a,e) protein residues interacting with the compounds by Van der Waals interactions are highlighted in red, while hydrogen bonds are indicated by green dotted lines. Interacting residues found also for the other polymorphs are circled.
role. In more details, the hydrogenic interactions increase from 10 to 11 and new hydrogen bonds are formed with α2 Arg148, Arg161, Trp152, Lys155, Glu157, which adds up to the one formed with Asn77 (Fig. 6e) already observed above with the other isoforms (Fig. 6a). The electrostatic landscape is highly affected by the different sequence present in the α2 domain: CPT-11 in fact is observed in a different conformation (Fig. 6f) to match the different landscape of this mutant resentiing a positive electrostatic potential along all the substituted chain (Fig. 6g) and partially quenching the negative charge of the protein fragment observed for most common polymorphs (Fig. 6c). Nevertheless CPT-11 in its newly found conformation is capable of high complementarity (Fig. 6g).

The presence of a larger binding pattern observed for HLA-G*01:05 N with respect to the most common polymorphs suggests that once the CPT-11 is bound to the protein it could be sequestered and interfere with its activity. To clarify this picture and get some further insight on the effects of mutations on the behaviour of CPT-11 on HLA-G, 130 ns molecular dynamics simulations of each complex in water were run. The complexes binding energy was estimated by scoring the trajectories with the scoring function of Autodock VINA observing relevant interactions, between 5 and 10 kcal/mol, along the whole simulated time for all the polymorphs (Fig. 7a–d). In general CPT-11, while being mobile in the protein binding cleft, does not leave the protein. The effect of point mutations is confirmed to be minor: the molecule is observed to move in the cleft, but never leave it completely (Fig. 7e–g and insets therein). This can be appreciated by following the root mean squared deviation (RMSD) of CPT-11 and each polymorph backbone in the frame of the respective protein backbone (Fig. 7h). The protein backbone RMSD below 0.3 nm observed for most polymorphs indicates that the protein fragments do not undergo dramatic rearrangements even if, as expected, the value reaches 0.5 nm for G*01:05 N suggesting a rearrangement of its frameshifted domain. In this latter case, where CPT-11 is kept into place thanks to several hydrogen bonds which give stability to the complex, only smaller rearrangements are observed in the CPT-11 atom positions with respect to those observed for the most common polymorphs (Fig. 7h).

Discussion and Conclusions

Current results in the field of immune-oncology underline the relevance of study the immune system actors as a strategy to ameliorate the clinical outcome of patients suffering of a number of cancers. In particular, the recent work of Pagès and colleagues highlighted the importance of using the Immunoscore as new method to stratify patients ensuring a more precise treatment with a better prognostic value in colon cancer. Here we maintain that HLA-G could facilitate tumor immune escape phenomenon, invasiveness, disease progression. We observed that high soluble HLA-G levels were associated with diminished irinotecan and then BI levels, with a possible effect on the clinical outcomes of these patients. A correlation between positive tumor expression of HLA-G and distant metastasis suggested that HLA-G could facilitate tumor immune escape phenomenon, invasiveness, disease progression. We observed that patients with high soluble HLA-G levels in plasma exhibited a significant predictive value of worse survival. High levels of the peripheral soluble HLA-G are usually associated to a negative prognostic value in CRC. However, the relation of the
sHLA-G levels with the prognosis could be considered a controversial issue. It was raised a critical aspect in the techniques used in CRC for the quantification of HLA-G protein expression that could provide an HLA-G overestimation predominantly in the immunohistochemical studies. Moreover, the HLA-G-targeting antibodies currently available do not allow detecting the expression of all the HLA-G isoforms but only of the most frequent.

Our analysis of the pharmacokinetic parameters suggested a possible mechanism of CPT-11 capture by the HLA-G protein that may alter the interaction of HLA-G with its target receptors, blocking the induction of tolerogenic effects that induces tumor immune escape. This hypothesis was confirmed by testing the association between sHLA-G and CPT-11 by spectrophotometric analysis and molecular modeling. Both confirmed the off-target association between the two compounds. In particular, for the first time, molecular modeling further revealed a different association mechanism for the rarer mutant HLA-G*01:05 N with respect to the most common HLA-G*01:01, HLA-G*01:03, and HLA-G*01:04 HLA-G polymorphs. The presence of HLA-G*01:05 N was associated to the HLA-G UTR-2 haplotype related to a lower sHLA-G expression and it was already demonstrated to correlate with a decreased risk of non-small cell lung cancer in Tunisian population. No specific data for HLA-G*01:05 N in CRC were found in the literature, nevertheless it was demonstrated that HLA-G UTR-2 haplotype has a predictive role of neurotoxicity risk in non-metastatic CRC treated with FOLF0X4 (folinic acid/5-fluorouracil/oxaliplatin).

Generally, HLA-G*01:05 N has a low frequency in the world, except for the Middle East populations, in particular North Indian and certain African population as Shona. The evolutive reason of this frequency distribution is not yet known although it has been hypothesized an origin by a founder effect or related to HLA-G*01:05N-allele functions. It has been already reported the HLA-G*01:05 N allele may provide some selective advantage such as avoiding maternal rejection and improving of immune response against some infections in healthy population. Moreover, immune response can also affect cancer development and then the effect of HLA-G*01:05 N allele on cancer is an intriguing issue that needs further investigation. In this HLA-G*01:05 N polymorph we found a larger number of hydrophobic interactions and hydrogen bonds, and also an electrostatic complementarity to keep CPT-11 bound to the pocket. The discovery of this novel HLA-G/ CPT-11 interaction suggests two hypothesis of the effect that could be had in patients: (1) it could alter the interaction of HLA-G with its receptors located on the immune system cells, modifying its mechanism of inhibition of immune responses; (2) it could affect the pharmacological effect of the CPT-11, altering its pharmacokinetics. In the first case, this interaction may inhibit the tolerogenic functions of HLA-G against cancer and this could explain good prognostic results found in the literature. In the second hypothesis, we could also have some effects on clinical aspects. A further investigation, also by means of localised mutations, on the interactions between HLA-G variants with CPT-11 metabolites could help to better explain their clinical implication in the treatment of patients with mCRC.

In conclusion, we observed a novel and interesting interaction between irinotecan and HLA-G polymorphs and the more resistant association of irinotecan to HLA-G*01:05 N offer a new opportunity to better evaluate the effect of less common isoforms and maybe to clarify the apparently controversial differences in the effect of HLA-G levels on clinical outcomes reported in several studies conducted in population with different ethnicities and treatments affected by cancer.

The main limit of our study is represented by the small number of patients with mCRC in which the plasmatic concentration of sHLA-G was retrospectively tested. Considering that the inverse correlation between the PK parameters and sHLA-G levels was observed in a small subgroup of patients, our results should be viewed as hypothesis generating to be validated in a further work though a correlation analysis with clinical data such as response to treatment and survival, with a proper sample size of patients affected by mCRC and homogeneously treated with irinotecan-based regimen. However, the preliminary data concerning the off-target CPT-11/HLA-G association sustain this finding. Indeed, one important strength of this study, is that, to our knowledge, this is the first exploratory investigation about the unspecific interaction between HLA-G and a chemotherapeutic drug currently used to treat patients with different advanced malignancies, including mCRC.

Methods

Patients clinical data and treatment. Clinical data, genomic DNA from blood samples and plasma samples were obtained from patients diagnosed with mCRC prospectively collected by Toffoli and colleagues for two previous published studies. Inclusion criteria for our retrospective study was defined by plasma sample availability: 25 samples derived from the first study and 15 from the genotype-driven phase I study published in 2010. All the plasma samples analyzed in this study were collected prior to FOLFIRI administration. About the second study, patients were selected for UGT1A1*1/*1 and UGT1A1*1/*28 genotypes and treated with FOLFIRI regimen: irinotecan was administered at doses higher than the standard 180 mg/m2 starting from 215 mg/m2 with a 20% increase every 2-weeks dose until a dose of 370 mg/m2 for UGT1A1*1/*28 patients and of 420 mg/m2 for UGT1A1*1/*1 patients, with unchanged dose of infusional FU/LV. FOLFIRI was discontinued because of disease progression, intolerable side effects, patient refusal, or physician assessment. According to the eligible criteria of the study, patients who carried the UGT1A1*28/*28 were excluded. The institutional review board of each participating institution and the Ethics Committee of the Centro di Riferimento Oncologico (CRO) of Aviano had approved the study protocol (CRO-26-2002 and CRO-34-2005), and all patients signed a written informed consent for a genetic analysis before entering the study. All the analyses were performed in accordance with the Declaration of Helsinki principles.

Assay for plasma sHLA-G. We analyzed the 40 available EDTA plasma samples using the sHLA-G enzymed-linked immunosorbent assay (ELISA) kit (BioVendor–Laboratorní medicína a.s., Brno, Czech Republic), a sandwich enzyme immunoassay for the quantitative measurement of sHLA-G, according to the manufacturer’s instructions. This ELISA assay detects both membrane shedded HLA-G1 and soluble HLA-G5. The absorbance was measured by Infinite F200 PRO (TECAN, Männedorf, Switzerland) at 450 nm with the
We calculated the molar concentration though the Beer-Lambert law using the theoretical extinction coefficient in cuvettes with a pathlength of 10 mm and a volume of 700 μl for hla-g.html (NCBI Reference Sequence: NP 002118.1 or HLA00939 G*01:01). A fix concentration (0.1 μM) was prepared setting, we performed a titration assay measuring the fluorescence emission spectra of HLA-G and CPT-11, as Ser2. Chain A of structure 1YDP was used as a template for all the mutants. The most common sequence in the first 26 residues with respect to the sequences linked above), and the first amino acid of the chain was labelled hla-g.html. Absorption spectra of blank, HLA-G and CPT-11 were recorded on the Cary Eclipse UV-Vis Spectrophotometer (Agilent Technologies, Santa Clara, CA, USA) and were the mean of 4 spectra acquisitions. The final concentrations analyzed were 0.01, 0.05 and 0.1 μM for HLA-G, and 0.01, 0.05, 0.1, 1, 5, 10, 25, 50 μM for CPT-11. Quartz cuvettes with a pathlength of 10 mm and a volume of 700 μl (Hellma-Analytics, Müllheim, Germany) were used. We calculated the molar concentration though the Beer-Lambert law using the theoretical extinction coefficient obtained from the primary sequence of the proteins calculated with the ExpASy ProtParam tool (http://www.expasy.org/tools/pi_tool.html).

Fluorescence. Fluorescence emission spectra of blank, HLA-G and CPT-11 were measured using the Cary Eclipse Fluorescence Spectrophotometer (Agilent Technologies, Santa Clara, CA, USA). The concentrations analyzed were 0.01, 0.05 and 0.1 μM for HLA-G, and 1, 5, 10, 15, 20 μM for CPT-11. Emission spectrum of the molecules was recorded from 280 to 550 nm and from 365 to 550 nm at an excitation wavelength of 275/280 and 360 nm, respectively. The emission and excitation slits widths were set at 2.5 and 5 nm with a photomultiplier tube (PMT) detector voltage of 800 and 500 Volts, respectively. Fluorescence quartz cuvettes with a pathlength of 3 mm × 3 mm and a volume of 45 μl (Hellma-Analytics, Müllheim, Germany) were used. Using the same instrument setting, we performed a titration assay measuring the fluorescence emission spectra of HLA-G and CPT-11, adding to a fix concentration (0.1 μM) of HLA-G a certain amount of CPT-11 each time, changing concentrations of CPT-11 in solution to 1, 5, 10, 15, 20 μM during the interaction. Data were fitted using Microsoft Excel Solver together with SolverAID, the latter part of R. de Levie MacroBundle (v.12 May 2012).

Homology modelling. We chose HLA-G sequences corresponding to the α1 and α2 domains (aa 2–182) of HLA-G*01:01, HLA-G*01:03, HLA-G*01:04, HLA-G*01:05 N coding alleles from http://hlaalleles.expasy.org/data/hla-g.html (NCBI Reference Sequence: NP 002118.1 or HLA00939 G*01:01:01 in ftp://ftp.ebi.ac.uk/pub/databases/ftpdb/imgt/hla/fasta/G_prot.fasta). All modelled sequences started with SHSMRYFSAV (thus discarding the first 26 residues with respect to the sequences linked above), and the first amino acid of the chain was labelled as Ser2. Chain A of structure 1YDP was used as a template for all the mutants. The most common sequence G*01:01 (corresponding to the experimental sequence) presents three mutations with respect to the 1YDP: S42C, I110L, R115Q. All the sequences but one were reconstructed by alignment and fitting with DeepView - Swiss-PdbViewer 4.1 and G*01:05 N was built with Swiss Model. All the models were minimized by first minimizing the protein side chains alone then whole protein with the AMBER99SB force field as implemented in GROMACS package v. 2016.1.

Molecule preparation and docking. The irinotecan initial conformation was protonated, minimized with AM1 method as implemented in MOPAC 2016. The molecule was docked into each protein representative conformation as described above. The system was prepared with AutoDock tools, and docked with AutoDock. We used Lamarckian Genetic Algorithm with docking box (26.250 × 26.250 × 41.25)Å centred on the alpha carbon of Tyr7 with 0.375 Å grid spacing. The docking was performed with 1000 runs and 2,500,000 maximum numbers of evaluations and standard parameters. End–conformations were clustered and the representative conformation of each cluster was chosen. Comparison between 1YDP crystal structure and its redocked ligand had RMSD 0.9 nm, thus validating the method. End–conformations of HLA-G*01:03, HLA-G*01:04, HLA-G*01:05 N were further visually inspected for the occurrence of the first ranked irinotecan pose found for HLA-G*01:01. 2D ligand–protein interaction diagrams were generated with LigPlot+. Representative conformations were thus minimized by first minimizing the protein side chains alone; then whole protein and finally the whole system by constraining selected portions of the system as reported below: Surface electrostatic potentials in the form of Coulomb potentials with distance dependent dielectric constant ε = 80.0 (water), at 1.4 Å from the surface, and 298 K as implemented in UCSF Chimera.
Molecular dynamics simulations. Each selected HLA-G/irinotecan complex was minimised by constraining selected portions of the system and progressively releasing them. The complex was then hydrated in a cubic box with a tip3p water layer of 0.7 nm and the whole system was minimised again. AMBER99SB force field was used with ligand topologies built with Antechamber. Antechamber and OPLS force fields were validated by comparing the molecular coordinates after minimisation with respect to the semiempirical QM calculation (RMSD ~ 0.013 nm). NVT and NPT equilibrations were performed for 100 ps, followed by 130 ns NPT production run at 300 K with 2 fs iteration time step, Verlet integrator, LINCS constraint, and periodic boundary conditions. All the simulations and their analysis were run as implemented in the GROMACS package v. 2016.1. Simulations were run on Marconi (CINECA, Italy).

Received: 8 January 2020; Accepted: 27 April 2020; Published online: 29 May 2020

References

1. Lin, A. & Yan, W.-H. Human leukocyte antigen-G (HLA-G) expression in cancers: roles in immune evasion, metastasis and target for therapy. Mol. Med. 21(1), 782–791 (2015).
2. Rehmann, Y. et al. Association of soluble HLA-G plasma levels with HLA-G alleles. Tissue Antigens 57(1), 15–21 (2001).
3. Lin, A. et al. HLA-G expression in human ovarian carcinoma correlates NK cell function. Ann. Oncol. 18(11), 1804–1809 (2007).
4. Wang, Y., Ye, Z., Meng, X.-Q. & Zheng, S.-S. Expression of HLA-G in patients with hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 10(2), 158–163 (2011).
5. Lin, A. et al. Clinical relevance and functional implications for human leukocyte antigen-γ expression in non-small-cell lung cancer. J. Cell. Mol. Med. 14(9), 2318–2329 (2010).
6. Zheng, N. et al. Up-regulation of HLA-G expression in cervical premalignant and malignant lesions. Tissue antigens 77(3), 218–224 (2011).
7. Curigliano, G., Criscitiello, C., Gelao, L. & Goldhirsch, A. Molecular pathways: human leukocyte antigen G (HLA-G). Clin. Cancer Res. 19(20), 5564–5571 (2013).
8. Dumont, C. et al. CD8+ PD-1–ILT2+ T Cells Are an Intratumoral Cytotoxic Population Selectively Inhibited by the Immune-Checkpoint HLA-G. Cancer immunology Res. 7(10), 1619–1632 (2019).
9. Pagès, F. et al. International validation of the consensus Immunoscope for the classification of colon cancer: a prognostic and accuracy study. Lancet 391(10135), 2128–2139 (2018).
10. Zhang, R.-L. et al. Predictive value of different proportion of lesion HLA-G expression in colorectal cancer. Oncotarget 8(64), 107441 (2017).
11. Fujita, K.-i., Kubota, Y., Ishida, H. & Sasaki, Y. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J. Gastroenterol. 21(43), 12234 (2015).
12. Nishimura, T. et al. Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes. Gastric Cancer 20(4), 655–662 (2017).
13. Noda, K. et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346(2), 85–91 (2002).
14. Glassman, D. C. et al. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. BMC Cancer 18(1), 693 (2018).
15. Verschraegen, C. F. Irinotecan for the treatment of cervical cancer. Oncology 165(Suppl 5), 32–34 (2002).
16. Musa, F. et al. Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer. Gynecol. Oncol. 144(2), 279–284 (2017).
17. Mathijsen, R. H., Loos, W. J., Verweij, J. & Sparreboom, A. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Cancer Drug Targets 2(2), 103–123 (2002).
18. Pommier, Y. Drugging topoisomerase: lessons and challenges. ACS Chem. Biol. 8(1), 82–95 (2013).
19. Anthony, L. Irinotecan toxicity. Curr. Opin. Support. Palliat. Care 1(1), 35–39 (2007).
20. Dean, L. Irinotecan therapy and UGT1A1 genotype. In: Medical Genetics Summaries [Internet]. National Center for Biotechnology Information (US) (2018).
21. de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijsen, R. H. J. & Bins, S. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clin. Pharmacokinet. 57(10), 1229–1254 (2018).
22. Malataste, L. et al. Simultaneous quantification of Gemcitabine and Irinotecan hydrochloride in rat plasma by using high performance liquid chromatography-diode array detector. J. Pharm. Biomed. Anal. 159, 192–199 (2018).
23. Bosocco, B. et al. Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application. PLoS ONE 15(2), e0228822 (2020).
24. Yan, W.-H. HLA-G expression in cancers: potential role in diagnosis, prognosis and therapy. Endocrine, Metab. Immune Disorders Drug Targets 11(1), 76–89 (2011).
25. Castelli, E. C. et al. In silico analysis of microRNAs targeting the HLA-G 3′ untranslated region alleles and haplotypes. Hum. Immunol. 70(12), 1020–1025 (2009).
26. Tronik-Le Roux, D. et al. Novel landscape of HLA-G isoforms expressed in clear cell renal cell carcinoma patients. Mol. Oncol. 11(1), 1561–1578 (2017).
27. Lin, A. & Yan, W.-H. Heterogeneity of HLA-G expression in cancers: Facing the challenges. Front. Immunol. 9, 2164 (2018).
28. Kuroki, K. et al. Structural and Functional Basis for LILRB Immune Checkpoint Receptor Recognition of HLA-G Isoforms. The Journal of Immunology (2019).
29. HoWangYin, K.-Y. et al. Multimeric structures of HLA-G isoforms function through differential binding to LILRB receptors. Cell. Mol. Life Sci. 69(23), 4041–4049 (2012).
30. Castelli, E. C. et al. Insights into HLA-G genetics provided by worldwide haplotype diversity. Front. Immunology 5, 476 (2014).
31. Elvid, T. V. F., Hylenius, S., Rørbye, C. & Nielsen, L. G. HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels. Immunogenetics 55(2), 63–79 (2003).
32. Carlini, F. et al. HLA-G UTR haplotype conservation in the Malian population: association with soluble HLA-G. PLoS ONE 8(12), e82517 (2013).
33. Rizzo, R. et al. HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism. Haematologica 99(5), 888–896 (2014).
34. Di Cristofaro, J. et al. HLA-G*01:04 - UTR3 Recipient Correlates With Lower Survival and Higher Frequency of Chronic Rejection After Lung Transplantation. Am. J. Transpl. 15(9), 2413–2420 (2015).
35. Craenmehr, M. H. et al. Soluble HLA-G levels in seminal plasma are associated with HLA-G 3′ UTR genotypes and haplotypes. HLA 94(4), 339–346 (2019).
36. Sipak, O. et al. The Relationship between the HLA-G Polymorphism and sHLA-G Levels in Parental Pairs with High-Risk Pregnancy. *Int. J. Environ. Res. public health* 16(9), 1546 (2019).
37. Sipak, O. et al. Molecular Analysis of HLA-G in Women with High-Risk Pregnancy and Their Partners with Regard to Possible Complications. *Int. J. Environ. Res. public health* 16(6), 982 (2019).
38. Schwich, E. et al. Vesicular-Bound HLA-G as a Predictive Marker for Disease Progression in Epithelial Ovarian Cancer. *Cancers* 11(8), 1106 (2019).
39. Schwich, E. et al. HLA-G 3’ untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer. *Sci. Rep.* 9(1), 5407 (2019).
40. Garziera, M. et al. Association of the HLA-G 3’ UTR polymorphisms with colorectal cancer in Italy: a first insight. *Int. J. Immunogenet.* 43(1), 32–39 (2016).
41. Garziera, M. et al. HLA-G 3'UTR polymorphisms impact the prognosis of stage II-III CRC patients in fluoropyrimidine-based treatment. *PLoS ONE* 10(12), e0144000 (2015).
42. Garziera, M. et al. HLA-G 3’ UTR polymorphisms predict drug-induced G3-4 toxicity related to folinic acid/5-fluorouracil/oxlapatin (FOLFOX4) chemotherapy in non-metastatic colorectal cancer. *Int. J. Mol. Sci.* 18(7), 1366 (2017).
43. Toffoli, G. et al. The role of UGT1A1* 28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. *J. Clin. Oncol.* 24(19), 3061–3068 (2006).
44. Kirana, C. et al. Soluble HLA-G is a differential prognostic marker in sequential colorectal cancer disease stages. *Int. J. Cancer* 140(11), 2577–2586 (2017).
45. Guo, Z.-Y. et al. Predictive value of HLA-G and HLA-E in the prognosis of colorectal cancer patients. *Cell. immunology* 293(1), 10–16 (2015).
46. Zeestraten, E. et al. Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. *Br. J. cancer* 110(2), 439 (2014).
47. Li, J.-B. et al. Importance of the plasma soluble HLA-G levels for prognostic stratification with traditional prognosticators in colorectal cancer. *Oncofarget* 8(30), 48854 (2017).
48. Rouas-Freiss, N., Moreau, P., LeMaoult, J., Carosella, E. D. The dual role of HLA-G in cancer. *Journal of immunology research* 2014 (2014).
49. Rutten, M. et al. HLA-G expression is an independent predictor for improved survival in high grade ovarian carcinomas. *Journal of immunology research* 2014 (2014).
50. Swets, M. et al. HLA-G protein expression in colorectal cancer evaluated by immunohistochemistry and western blot analysis: Its expression characteristics remain enigmatic. *Clin. Immunol.* 194, 80–86 (2018).
51. Amor, A. B. et al. Human leukocyte antigen G polymorphism and expression are associated with an increased risk of non-small-cell lung cancer and advanced disease stage. *PLoS One* 11(8), e0161210 (2016).
52. Arnaiz-Villena, A. et al. HLA-G; A haplotypes in Amerindians (Ecuador): HLA-G* 01:05N World distribution. *Hum. immunology* 79(2), 89–90 (2018).
53. Arnaiz-Villena, A. et al. HLA-G; A haplotypes in Amerindians (Ecuador): HLA-G*01:05N World distribution. *Hum. Immunol.* 79(2), 89–90 (2018).
54. Toffoli, G. et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. *J. Clin. Oncol.* 28(5), 866 (2010).
55. Swinehart, D. The beer-lambert law. *J. Chem. Educ.* 39(7), 333 (1962).
56. Clements, C. S. et al. Crystal structure of HLA-G: a nonclassical MHC class I molecule expressed at the fetal–maternal interface. *Proc. Natl Acad. Sci.* 102(9), 3360–3365 (2005).

Acknowledgements
This study was supported by the funding received from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 633635 (DIACHEMO). SF acknowledges funding from the Italian Association for Cancer Research (AIRC) through the grant “My First AIRC grant” Rif.18510 (PI: Fortuna), and the CINECA Awards N. HP10C70TG1, 2018, for the availability of high performance computing resources and support.

Author contributions
L.S. and M.G. analysed the patients samples and analysed the samples data; G.T. provided clinical support; L.S., F.A. and S.G. performed the UV-Vis spectrophotometry and fluorescence spectroscopy measures and analysed the data; S.F. performed the molecular modelling and run the simulations, S.F. and S.G. analysed the computational results; L.S., M.G., S.F. and S.G. wrote the manuscript; L.S., M.G., G.T. and S.G. proposed and supervised the project; all authors revised and approved the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-65424-z.
Correspondence and requests for materials should be addressed to S.F.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.